Update on therapeutic of monoclonal antibodies

Abstract

Aim: The monoclonal antibody-based therapeutics is a continuously growing area, which is why we found it necessary to perform an update on the review we did two years ago.

Materials and methods: They conducted a narrative review of the technical changes made regarding expansion and / or modification of monoclonal antibodies directed marketed in our country. It also details all new monoclonal antibodies marketed for describing its main points. It also presents the most relevant alerts in relation to these molecules by reviewing the monthly reports of the Agencia Española de Medicamentos y ProductosSanitarios (AEMPS)and notes issued by various regulatory agencies. Finally, we have included the molecules used off label from our own hospital registry and those in various stages of clinical research through clinical trials web log.

Results: There have been 22 additions / modifications in monoclonal antibodies directed marketed until 2011. In relation to these molecules it has been published 12 alerts by regulatory agencies and laboratories manufacturers. Also there are 12 monoclonal antibodies that have been marketedin our country since then. The off-label uses of these molecules are varied highlighting dermatologyand immune system diseases such as requesting services. There are plenty of monoclonal antibodiesin clinical research, some of them as new molecules and in other cases to expand the repertoire ofindications thereof.

Conclusion: The knowledge in monoclonal antibody-based therapeutics requires regular updatesbecause of the research of new molecules, changes or expansion of indications in the molecules alreadyon the market and appearance of alerts during the pharmacovigilance.